Immunovant, Inc. (IMVT) short interest & options flow
NASDAQImmunovant reports today with one of the most striking options signals in the biotech space: the put/call ratio has collapsed to 0.09, nearly 1.7 standard deviations below its 20-day average of 0.22, and close to its 52-week low of 0.05. That is unusually aggressive call-side positioning, with traders loading up on upside exposure rather than hedging into the release. The stock…
- Market cap
- $6.57B
- Next earnings
- 5 Feb 2027
Key data as of 22 Nov 2026

IMVT news and analysis
RSSNo long-form analysis yet for IMVT. Pulse alerts and the live data picture are available on ORTEX.
Open IMVT on ORTEX →Want the live picture for IMVT?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IMVT — free to start on ORTEX.
Sign up for free →Open IMVT on ORTEX